Publications by authors named "Haihui Deng"
Article Synopsis
- Central venous catheterization is important for various medical procedures but can lead to serious complications, such as arterial puncture.
- A 74-year-old woman had a catheter accidentally placed in the wrong location during a procedure, necessitating a careful replacement strategy due to high surgical risks.
- The successful replacement of the catheter without complications, along with stable follow-up results, highlights the effectiveness of minimally invasive techniques and the need for ultrasound guidance to enhance safety.
Article Synopsis
- A study was conducted to evaluate the effectiveness and safety of combining lenvatinib, drug-eluting bead transarterial chemoembolization (DEB-TACE), and hepatic arterial infusion chemotherapy (HAIC) in treating large hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (PVTT).
- Researchers compared outcomes between two groups: those receiving Len+DEB-TACE+HAIC and those on Len+DEB-TACE alone, analyzing data from 205 patients across multiple hospitals in China.
- Results showed that the combination treatment (Len+DEB-TACE+HAIC) led to significantly better objective response rates, longer time to disease progression, and improved overall survival compared to the Len
Background: The combination of atezolizumab (ATZ) and bevacizumab (BVZ) was approved as first-line systemic therapy for advanced hepatocellular carcinoma (HCC) owing to its superior rates of response and patient survival. However, ATZ + BVZ is associated with increased risk of upper gastrointestinal (GI) bleeding, including arterial bleeding, which is rare and potentially fatal. We present a case of massive upper GI bleeding from a gastric pseudoaneurysm in a patient with advanced HCC who had been treated with ATZ + BVZ.
View Article and Find Full Text PDFArticle Synopsis
- Advanced abdominal lymph node (ALN) metastasis in hepatocellular carcinoma (HCC) typically results in poor outcomes due to limited treatment options; however, immunotherapy using PD-1 inhibitors shows promise.
- A case study details a 58-year-old man with progressive HCC who achieved complete response after being treated with tislelizumab, an immunotherapy drug, combined with local therapy (RFA) despite prior unsuccessful treatments.
- The findings suggest that using tislelizumab alone or in conjunction with localized treatments can provide a more effective approach for managing advanced HCC with ALN metastasis.